HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on TransCode Therapeutics (NASDAQ:RNAZ) and maintained a $12 price target.
August 15, 2023 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TransCode Therapeutics (NASDAQ:RNAZ) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $12.
The reiteration of a 'Buy' rating by a reputable analyst like Emily Bodnar from HC Wainwright & Co. is a positive signal for investors. The maintained price target of $12 indicates the analyst's confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100